Skip to main navigation Skip to search Skip to main content

Introduction and utilization of high priced HCV medicines across Europe; implications for the future

  • Winnie de Bruijn
  • , Cristina Ibáñez
  • , Pia Frisk
  • , Hanne Bak Pedersen
  • , Ali Alkan
  • , Patricia Vella Bonanno
  • , Ljiljana S. Brkicic
  • , Anna Bucsics
  • , Guillaume Dedet
  • , Jaran Eriksen
  • , Joseph O. Fadare
  • , Jurij Fürst
  • , Gisselle Gallego
  • , Isabella P. Godói
  • , Augusto A. Guerra Júnior
  • , Hakki Gürsöz
  • , Saira Jan
  • , Jan Jones
  • , Roberta Joppi
  • , Saim Kerman
    • Ott Laius, Newman Madzikwa, Einar Magnússon, Mojca Maticic, Vanda Markovic-Pekovic, Amos Massele, Olayinka Ogunleye, Aisling O'Leary, Jutta Piessnegger, Catherine Sermet, Steven Simoens, Celda Tiroyakgosi, Ilse Truter, Magnus Thyberg, Kristina Tomekova, Magdalena Wladysiuk, Sotiris Vandoros, Elif H. Vural, Corinne Zara, Brian Godman*
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Introduction and utilization of high priced HCV medicines across Europe; implications for the future'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases